AngioDynamics (NASDAQ: ANGO) awards RSUs and performance rights to SVP

Rhea-AI Filing Summary

Piccinini Laura reported acquisition or exercise transactions in this Form 4 filing.

AngioDynamics Inc. senior vice president of international operations Laura Piccinini received equity awards on July 15, 2026. She was granted 19,860 restricted stock units, each representing a contingent right to one common share, vesting in four equal annual installments from July 15, 2027 through July 15, 2030, bringing her direct common stock holdings to 78,388 shares. She also received 19,860 performance rights, each tied to one share of common stock, with between 0% and 200% of the target amount earned over a three-year period and a potential 20% adjustment, for a maximum payout of up to 240% of the target based on total shareholder return relative to a peer group.

Insider Trade Summary

Net Buyer: 19,860 shares

Net Buy 2 txns

Insider Piccinini Laura

Role SVP International

Type	Security	Shares	Price	Value
Grant/Award	Performance Right F2	19,860	$0.00	$0.00
Grant/Award	Common Stock F1	19,860	$0.00	$0.00

Holdings After Transaction: Performance Right — 19,860 shares (Direct); Common Stock — 78,388 shares (Direct)

Footnotes (2)

1. F1. The acquisition of 19,860 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 19,860 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
2. F2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Key Figures

Restricted stock units granted: 19,860 units Performance rights target granted: 19,860 rights Common shares held after award: 78,388 shares +2 more

5 metrics

Restricted stock units granted 19,860 units RSUs granted to SVP International on July 15, 2026; vest over four years

Performance rights target granted 19,860 rights Performance rights each representing one share of common stock, granted July 15, 2026

Common shares held after award 78,388 shares Direct AngioDynamics common stock holdings of Laura Piccinini after RSU grant

Maximum performance payout 240% of target Maximum shares earned based on total shareholder return over a three-year period

Annual RSU vesting portion 25% per year RSUs vest in four equal annual installments from July 15, 2027 to July 15, 2030

Key Terms

restricted stock units, performance right, total shareholder return, peer group of companies

4 terms

restricted stock units financial

"represents 19,860 restricted stock units, each of which represents a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance right financial

"Each performance right represents a contingent right to receive one share"

total shareholder return financial

"Between 0% and 200% of the target number will be earned based on total shareholder return"

Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.

peer group of companies financial

"based on total shareholder return relative to a peer group of companies over a three-year"

FAQ

What equity awards did AngioDynamics (ANGO) grant to Laura Piccinini?

AngioDynamics granted SVP International Laura Piccinini 19,860 restricted stock units and 19,860 performance rights on July 15, 2026. Each unit or right represents a contingent right to receive one share of common stock, subject to time-based vesting and performance conditions.

How do the restricted stock units for AngioDynamics (ANGO) SVP vest?

The 19,860 restricted stock units vest in four equal annual installments. Starting July 15, 2027, 25% of the RSUs vest each year on July 15, so remaining tranches vest on July 15, 2028, 2029 and 2030, assuming continued service and conditions are met.

How are AngioDynamics (ANGO) performance rights for Laura Piccinini earned?

Each of the 19,860 performance rights can earn between 0% and 200% of target, with a possible additional 20% adjustment. The final payout, up to 240% of target, depends on total shareholder return versus a peer group over a three-year performance period.

How many AngioDynamics (ANGO) common shares does Laura Piccinini hold after these awards?

Following the grant of 19,860 restricted stock units, Laura Piccinini is reported to directly hold 78,388 shares of AngioDynamics common stock. This figure reflects her post-transaction direct ownership as of the July 15, 2026 equity award date.

Were Laura Piccinini’s AngioDynamics (ANGO) awards made under a Rule 10b5-1 plan?

The filing indicates the awards were not made under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is explicitly unchecked, and related footnotes do not reference any pre-arranged trading arrangement for these grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/22/2026 - 08:06 PM Accepted by SEC EDGAR 07/22/2026 - 08:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piccinini Laura

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP International

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		19,860(1)	A	$0	78,388	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Right	(2)	07/15/2026		A		19,860		(2)	(2)	Common Stock	19,860	$0	19,860	D

Explanation of Responses:

1. The acquisition of 19,860 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 19,860 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)